Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
NCT03295227Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2017
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in thymoma and thymic carcinoma (TC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events up to 3 years. Started Dec 2017; status: recruiting.
02
Drugs
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT03295227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295227.